{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T19:41:37Z","timestamp":1772134897942,"version":"3.50.1"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA245081"],"award-info":[{"award-number":["R01CA245081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R42CA268138"],"award-info":[{"award-number":["R42CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA268138"],"award-info":[{"award-number":["R44CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA245081"],"award-info":[{"award-number":["R01CA245081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R42CA268138"],"award-info":[{"award-number":["R42CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA268138"],"award-info":[{"award-number":["R44CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA245081"],"award-info":[{"award-number":["R01CA245081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R42CA268138"],"award-info":[{"award-number":["R42CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA268138"],"award-info":[{"award-number":["R44CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA245081"],"award-info":[{"award-number":["R01CA245081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R42CA268138"],"award-info":[{"award-number":["R42CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA268138"],"award-info":[{"award-number":["R44CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA245081"],"award-info":[{"award-number":["R01CA245081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R42CA268138"],"award-info":[{"award-number":["R42CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA268138"],"award-info":[{"award-number":["R44CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA245081"],"award-info":[{"award-number":["R01CA245081"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R42CA268138"],"award-info":[{"award-number":["R42CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA268138"],"award-info":[{"award-number":["R44CA268138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The treatment of acute myeloid leukemia (AML) remains a challenge due to disease heterogeneity, which undermines efforts to develop targeted therapeutics, leaving conventional chemotherapy as the standard of care (SOC). Sialic acid binding Ig-like lectin 3 (CD33) is a myeloid cell surface glycoprotein that is highly expressed on AML blasts. However, while ~90% of AML cases express CD33, 50% of these patients harbor a single nucleotide polymorphism (SNP) that eliminates the antibody binding epitope for existing CD33-targeted antibody therapeutics. In this study, we developed an immunotherapy (M2T-CD33) that targets CD33 directly to MHC class II (MHCII) molecules on antigen presenting cells for enhanced presentation to the immune system. We found that M2T-CD33 induces a robust polyclonal anti-CD33 humoral response composed of the full immunoglobulin repertoire. M2T-CD33 induced an anti-AML response in a syngeneic mouse model that was dependent on CD4+ and CD8+\u2009T cells. The immune response was elicited against both the full length and spliced version of CD33 and showed no evidence of toxicity at concentrations 40-fold higher than the efficacious dose. Finally, M2T-CD33 was enhanced by combinations with anti-PD-1 therapy. These experiments demonstrate the preclinical potential of M2T-CD33 in AML and emphasize the importance of MHCII for cancer immunotherapy.<\/jats:p>","DOI":"10.1038\/s41408-025-01391-w","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T15:35:19Z","timestamp":1763393719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A superantigen-based MHC class II-targeted cancer immunotherapy for the treatment of acute myeloid leukemia"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0669-8190","authenticated-orcid":false,"given":"Lena","family":"Golick","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reeder M.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leticia","family":"Reyes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia","family":"St. Thomas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Klinzing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3247-6734","authenticated-orcid":false,"given":"Erin C.","family":"O\u2019Connor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2491-9866","authenticated-orcid":false,"given":"Leonardo M. R.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9181-2180","authenticated-orcid":false,"given":"Nathan G.","family":"Dolloff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"1391_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1391_CR2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/cncr.33458","volume":"127","author":"K Sasaki","year":"2021","unstructured":"Sasaki K, Ravandi F, Kadia TM, DiNardo CD, Short NJ, Borthakur G, et al. De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1980 to 2017. Cancer. 2021;127:2049\u201361.","journal-title":"Cancer"},{"key":"1391_CR3","doi-asserted-by":"publisher","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325\u201336.","journal-title":"Blood"},{"key":"1391_CR4","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"1391_CR5","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.5045\/br.2020.S002","volume":"55","author":"H Kim","year":"2020","unstructured":"Kim H. Treatments for children and adolescents with AML. Blood Res. 2020;55:S5\u2013S13.","journal-title":"Blood Res"},{"key":"1391_CR6","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41392-020-00361-x","volume":"5","author":"JL Carter","year":"2020","unstructured":"Carter JL, Hege K, Yang J, Kalpage HA, Su Y, Edwards H, et al. Targeting multiple signaling pathways: the new approach to acute myeloid leukemia therapy. Signal Transduct Target Ther. 2020;5:288.","journal-title":"Signal Transduct Target Ther"},{"key":"1391_CR7","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1182\/blood-2012-03-362608","volume":"120","author":"U Creutzig","year":"2012","unstructured":"Creutzig U, van den Heuvel-Eibrink MM, Gibson B, Dworzak MN, Adachi S, de Bont E, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120:3187\u2013205.","journal-title":"Blood"},{"key":"1391_CR8","first-page":"83","volume":"64","author":"E Ward","year":"2014","unstructured":"Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64:83\u2013103.","journal-title":"CA Cancer J Clin"},{"key":"1391_CR9","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"1391_CR10","doi-asserted-by":"publisher","first-page":"181","DOI":"10.5045\/br.2023.2023152","volume":"58","author":"JH Lee","year":"2023","unstructured":"Lee JH, Ju HY, Hyun JK, Kim SJ, Cho HW, Lee JK, et al. Treatment outcome and prognostic factors in relapsed pediatric acute myeloid leukemia. Blood Res. 2023;58:181\u20136.","journal-title":"Blood Res"},{"key":"1391_CR11","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nm.4439","volume":"24","author":"H Bolouri","year":"2018","unstructured":"Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24:103\u201312.","journal-title":"Nat Med"},{"key":"1391_CR12","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.4049\/jimmunol.174.5.2591","volume":"174","author":"PA Antony","year":"2005","unstructured":"Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, et al. CD8+ T cell immunity against a tumor\/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol. 2005;174:2591\u2013601.","journal-title":"J Immunol"},{"key":"1391_CR13","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1158\/0008-5472.CAN-10-1322","volume":"70","author":"R Bos","year":"2010","unstructured":"Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 2010;70:8368\u201377.","journal-title":"Cancer Res"},{"key":"1391_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1158\/0008-5472.CAN-12-1127","volume":"73","author":"EH Aarntzen","year":"2013","unstructured":"Aarntzen EH, De Vries IJ, Lesterhuis WJ, Schuurhuis D, Jacobs JF, Bol K, et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res. 2013;73:19\u201329.","journal-title":"Cancer Res"},{"key":"1391_CR15","doi-asserted-by":"publisher","first-page":"4685","DOI":"10.1200\/JCO.2008.20.6789","volume":"27","author":"ML Disis","year":"2009","unstructured":"Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, et al. Concurrent trastuzumab and HER2\/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol. 2009;27:4685\u201392.","journal-title":"J Clin Oncol"},{"key":"1391_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ccell.2022.03.006","volume":"40","author":"JR Veatch","year":"2022","unstructured":"Veatch JR, Lee SM, Shasha C, Singhi N, Szeto JL, Moshiri AS, et al. Neoantigen-specific CD4(+) T cells in human melanoma have diverse differentiation states and correlate with CD8(+) T cell, macrophage, and B cell function. Cancer Cell. 2022;40:393\u2013409.e9","journal-title":"Cancer Cell"},{"key":"1391_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00262-021-02976-7","volume":"71","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chimenti MS, Strouse C, Weiner GJ. T cells, particularly activated CD4(+) cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity. Cancer Immunol Immunother. 2022;71:237\u201349.","journal-title":"Cancer Immunol Immunother"},{"key":"1391_CR18","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1146\/annurev-immunol-103019-085803","volume":"38","author":"M Ruterbusch","year":"2020","unstructured":"Ruterbusch M, Pruner KB, Shehata L, Pepper M. In Vivo CD4(+) T cell differentiation and function: revisiting the Th1\/Th2 Paradigm. Annu Rev Immunol. 2020;38:705\u201325.","journal-title":"Annu Rev Immunol"},{"key":"1391_CR19","doi-asserted-by":"publisher","first-page":"5426","DOI":"10.1016\/j.vaccine.2006.03.050","volume":"24","author":"S Fougeray","year":"2006","unstructured":"Fougeray S, Brignone C, Triebel F. A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: preclinical evaluation of IMP321. Vaccine. 2006;24:5426\u201333.","journal-title":"Vaccine"},{"key":"1391_CR20","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","volume":"55","author":"T Maruhashi","year":"2022","unstructured":"Maruhashi T, Sugiura D, Okazaki IM, Shimizu K, Maeda TK, Ikubo J, et al. Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity. Immunity. 2022;55:912\u201324.e8","journal-title":"Immunity"},{"key":"1391_CR21","doi-asserted-by":"crossref","unstructured":"FDA approves anti-LAG3 checkpoint. Nat Biotechnol. 2022;40:625.","DOI":"10.1038\/s41587-022-01331-0"},{"key":"1391_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/BF00241263","volume":"39","author":"B Huard","year":"1994","unstructured":"Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics. 1994;39:213\u20137.","journal-title":"Immunogenetics"},{"key":"1391_CR23","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.chembiol.2023.05.003","volume":"30","author":"L Huang","year":"2023","unstructured":"Huang L, Zhang J, Wei B, Chen S, Zhu S, Qi W, et al. Small-molecule MHC-II inducers promote immune detection and anti-cancer immunity via editing cancer metabolism. Cell Chem Biol. 2023;30:1076\u201389.e11","journal-title":"Cell Chem Biol"},{"key":"1391_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46558-4","volume":"15","author":"J Long","year":"2024","unstructured":"Long J, Chen X, He M, Ou S, Zhao Y, Yan Q, et al. HLA-class II restricted TCR targeting human papillomavirus type 18 E7 induces solid tumor remission in mice. Nat Commun. 2024;15:2271.","journal-title":"Nat Commun"},{"key":"1391_CR25","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1200\/JCO.2017.74.5463","volume":"35","author":"YC Lu","year":"2017","unstructured":"Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, et al. Treatment of patients with metastatic cancer using a major histocompatibility complex class ii-restricted T-cell receptor targeting the cancer germline antigen MAGE-A3. J Clin Oncol. 2017;35:3322\u20139.","journal-title":"J Clin Oncol"},{"key":"1391_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1002\/jcph.1730","volume":"61","author":"JE Maakaron","year":"2021","unstructured":"Maakaron JE, Rogosheske J, Long M, Bachanova V, Mims AS. CD33-Targeted therapies: beating the disease or beaten to death?. J Clin Pharm. 2021;61:7\u201317.","journal-title":"J Clin Pharm"},{"key":"1391_CR27","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri2056","volume":"7","author":"PR Crocker","year":"2007","unstructured":"Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255\u201366.","journal-title":"Nat Rev Immunol"},{"key":"1391_CR28","doi-asserted-by":"crossref","unstructured":"Molica M, Perrone S, Mazzone C, Niscola P, Cesini L, Abruzzese E, et al. CD33 Expression and gentuzumab ozogamicin in acute myeloid leukemia: two sides of the same coin. Cancers (Basel). 2021;13:3214.","DOI":"10.3390\/cancers13133214"},{"key":"1391_CR29","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1200\/JCO.2016.71.2513","volume":"35","author":"JK Lamba","year":"2017","unstructured":"Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, et al. CD33 Splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase iii children\u2019s oncology group trial AAML0531. J Clin Oncol. 2017;35:2674\u201382.","journal-title":"J Clin Oncol"},{"key":"1391_CR30","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/10428194.2020.1827247","volume":"62","author":"A Ladha","year":"2021","unstructured":"Ladha A, Mannis G, Muffly L. Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. Leuk Lymphoma. 2021;62:257\u201363.","journal-title":"Leuk Lymphoma"},{"key":"1391_CR31","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1182\/blood.V98.4.988","volume":"98","author":"ML Linenberger","year":"2001","unstructured":"Linenberger ML, Hong T, Flowers D, Sievers EL, Gooley TA, Bennett JM, et al. Multidrug-resistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood. 2001;98:988\u201394.","journal-title":"Blood"},{"key":"1391_CR32","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","volume":"32","author":"AS Gamis","year":"2014","unstructured":"Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531. J Clin Oncol. 2014;32:3021\u201332.","journal-title":"J Clin Oncol"},{"key":"1391_CR33","doi-asserted-by":"publisher","first-page":"942","DOI":"10.3389\/fimmu.2019.00942","volume":"10","author":"A Popugailo","year":"2019","unstructured":"Popugailo A, Rotfogel Z, Supper E, Hillman D, Kaempfer R. Staphylococcal and streptococcal superantigens trigger B7\/CD28 costimulatory receptor engagement to hyperinduce inflammatory cytokines. Front Immunol. 2019;10:942.","journal-title":"Front Immunol"},{"key":"1391_CR34","doi-asserted-by":"publisher","first-page":"E6437","DOI":"10.1073\/pnas.1603321113","volume":"113","author":"R Levy","year":"2016","unstructured":"Levy R, Rotfogel Z, Hillman D, Popugailo A, Arad G, Supper E, et al. Superantigens hyperinduce inflammatory cytokines by enhancing the B7-2\/CD28 costimulatory receptor interaction. Proc Natl Acad Sci USA. 2016;113:E6437\u2013E46.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1391_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.731845","volume":"12","author":"AM Deacy","year":"2021","unstructured":"Deacy AM, Gan SK, Derrick JP. Superantigen recognition and interactions: functions, mechanisms and applications. Front Immunol. 2021;12:731845.","journal-title":"Front Immunol"},{"key":"1391_CR36","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1126\/science.2185544","volume":"248","author":"P Marrack","year":"1990","unstructured":"Marrack P, Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990;248:705\u201311.","journal-title":"Science"},{"key":"1391_CR37","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1084\/jem.189.1.89","volume":"189","author":"T Proft","year":"1999","unstructured":"Proft T, Moffatt SL, Berkahn CJ, Fraser JD. Identification and characterization of novel superantigens from Streptococcus pyogenes. J Exp Med. 1999;189:89\u2013102.","journal-title":"J Exp Med"},{"key":"1391_CR38","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/CVI.05446-11","volume":"19","author":"FJ Radcliff","year":"2012","unstructured":"Radcliff FJ, Loh JM, Ha B, Schuhbauer D, McCluskey J, Fraser JD. Antigen targeting to major histocompatibility complex class II with streptococcal mitogenic exotoxin Z-2 M1, a superantigen-based vaccine carrier. Clin Vaccin Immunol. 2012;19:574\u201386.","journal-title":"Clin Vaccin Immunol"},{"key":"1391_CR39","doi-asserted-by":"publisher","first-page":"5358","DOI":"10.1128\/IAI.73.9.5358-5366.2005","volume":"73","author":"DD Pless","year":"2005","unstructured":"Pless DD, Ruthel G, Reinke EK, Ulrich RG, Bavari S. Persistence of zinc-binding bacterial superantigens at the surface of antigen-presenting cells contributes to the extreme potency of these superantigens as T-cell activators. Infect Immun. 2005;73:5358\u201366.","journal-title":"Infect Immun"},{"key":"1391_CR40","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.4049\/jimmunol.182.3.1260","volume":"182","author":"N Dickgreber","year":"2009","unstructured":"Dickgreber N, Stoitzner P, Bai Y, Price KM, Farrand KJ, Manning K, et al. Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy. J Immunol. 2009;182:1260\u20139.","journal-title":"J Immunol"},{"key":"1391_CR41","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1016\/0264-410X(93)90123-F","volume":"11","author":"DL Skea","year":"1993","unstructured":"Skea DL, Douglas AR, Skehel JJ, Barber BH. The immunotargeting approach to adjuvant-independent immunization with influenza haemagglutinin. Vaccine. 1993;11:994\u20131002.","journal-title":"Vaccine"},{"key":"1391_CR42","doi-asserted-by":"crossref","unstructured":"Pishesha N, Harmand TJ, Rothlauf PW, Praest P, Alexander RK, van den Doel R, et al. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants. Proc Natl Acad Sci USA. 2021;118:e2116147118.","DOI":"10.1073\/pnas.2116147118"},{"key":"1391_CR43","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/0092-8674(90)90388-U","volume":"62","author":"P Dellabona","year":"1990","unstructured":"Dellabona P, Peccoud J, Kappler J, Marrack P, Benoist C, Mathis D. Superantigens interact with MHC class II molecules outside of the antigen groove. Cell. 1990;62:1115\u201321.","journal-title":"Cell"},{"key":"1391_CR44","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1056\/NEJM200009143431106","volume":"343","author":"J Klein","year":"2000","unstructured":"Klein J, Sato A. The HLA system. Second Two Parts N Engl J Med. 2000;343:782\u20136.","journal-title":"Second Two Parts N Engl J Med"},{"key":"1391_CR45","doi-asserted-by":"publisher","first-page":"6928","DOI":"10.4049\/jimmunol.169.12.6928","volume":"169","author":"FA Castelli","year":"2002","unstructured":"Castelli FA, Buhot C, Sanson A, Zarour H, Pouvelle-Moratille S, Nonn C, et al. HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity. J Immunol. 2002;169:6928\u201334.","journal-title":"J Immunol"},{"key":"1391_CR46","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1046\/j.1365-2249.2000.01290.x","volume":"121","author":"M Saifuddin","year":"2000","unstructured":"Saifuddin M, Spear GT, Chang C, Roebuck KA. Expression of MHC class II in T cells is associated with increased HIV-1 expression. Clin Exp Immunol. 2000;121:324\u201331.","journal-title":"Clin Exp Immunol"},{"key":"1391_CR47","doi-asserted-by":"crossref","unstructured":"Mopin A, Driss V, Brinster C. A detailed protocol for characterizing the murine C1498 cell line and its associated leukemia mouse model. J Vis Exp. 2016;14:54270.","DOI":"10.3791\/54270"},{"key":"1391_CR48","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1128\/MCB.23.12.4199-4206.2003","volume":"23","author":"EC Brinkman-Van der Linden","year":"2003","unstructured":"Brinkman-Van der Linden EC, Angata T, Reynolds SA, Powell LD, Hedrick SM, Varki A. CD33\/Siglec-3 binding specificity, expression pattern, and consequences of gene deletion in mice. Mol Cell Biol. 2003;23:4199\u2013206.","journal-title":"Mol Cell Biol"},{"key":"1391_CR49","doi-asserted-by":"publisher","first-page":"45128","DOI":"10.1074\/jbc.M108573200","volume":"276","author":"T Angata","year":"2001","unstructured":"Angata T, Hingorani R, Varki NM, Varki A. Cloning and characterization of a novel mouse Siglec, mSiglec-F: differential evolution of the mouse and human (CD33) Siglec-3-related gene clusters. J Biol Chem. 2001;276:45128\u201336.","journal-title":"J Biol Chem"},{"key":"1391_CR50","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/0896-8411(89)90013-9","volume":"2","author":"AS Klein-Schneegans","year":"1989","unstructured":"Klein-Schneegans AS, Kuntz L, Fonteneau P, Loor F. Serum concentrations of IgM, IgG1, IgG2b, IgG3 and IgA in C57BL\/6 mice and their congenics at the lpr (lymphoproliferation) locus. J Autoimmun. 1989;2:869\u201375.","journal-title":"J Autoimmun"},{"key":"1391_CR51","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1056\/NEJM199909303411407","volume":"341","author":"B Lowenberg","year":"1999","unstructured":"Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341:1051\u201362.","journal-title":"N Engl J Med"},{"key":"1391_CR52","doi-asserted-by":"crossref","unstructured":"Hoseini SS, Vadlamudi M, Espinosa-Cotton M, Tran H, Feng Y, Guo HF, et al. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021;9:e002509.","DOI":"10.1136\/jitc-2021-002509"},{"key":"1391_CR53","doi-asserted-by":"publisher","first-page":"4110","DOI":"10.1200\/JCO.2005.09.133","volume":"23","author":"EJ Feldman","year":"2005","unstructured":"Feldman EJ, Brandwein J, Stone R, Kalaycio M, Moore J, O\u2019Connor J, et al. Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol. 2005;23:4110\u20136.","journal-title":"J Clin Oncol"},{"key":"1391_CR54","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1002\/eji.1830230924","volume":"23","author":"P Matthys","year":"1993","unstructured":"Matthys P, Dillen C, Proost P, Heremans H, Van Damme J, Billiau A. Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon-gamma or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine levels. Eur J Immunol. 1993;23:2209\u201316.","journal-title":"Eur J Immunol"},{"key":"1391_CR55","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","volume":"6","author":"A Shimabukuro-Vornhagen","year":"2018","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M, et al. Cytokine release syndrome. J Immunother Cancer. 2018;6:56.","journal-title":"J Immunother Cancer"},{"key":"1391_CR56","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1309\/1WMW-CMXX-4WN4-T55U","volume":"118","author":"I Jilani","year":"2002","unstructured":"Jilani I, Estey E, Huh Y, Joe Y, Manshouri T, Yared M, et al. Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol. 2002;118:560\u20136.","journal-title":"Am J Clin Pathol"},{"key":"1391_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.39","volume":"4","author":"A Ehninger","year":"2014","unstructured":"Ehninger A, Kramer M, Rollig C, Thiede C, Bornhauser M, von Bonin M, et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia. Blood Cancer J. 2014;4:e218.","journal-title":"Blood Cancer J"},{"key":"1391_CR58","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1002\/cncr.21326","volume":"104","author":"RA Larson","year":"2005","unstructured":"Larson RA, Sievers EL, Stadtmauer EA, Lowenberg B, Estey EH, Dombret H, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer. 2005;104:1442\u201352.","journal-title":"Cancer"},{"key":"1391_CR59","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.3816\/CLM.2002.s.006","volume":"2","author":"LH Leopold","year":"2002","unstructured":"Leopold LH, Berger MS, Feingold J. Acute and long-term toxicities associated with gemtuzumab ozogamicin (Mylotarg) therapy of acute myeloid leukemia. Clin Lymphoma. 2002;2:S29\u201334.","journal-title":"Clin Lymphoma"},{"key":"1391_CR60","doi-asserted-by":"crossref","unstructured":"Jimbu L, Mesaros O, Popescu C, Neaga A, Berceanu I, Dima D, et al. Is there a place for PD-1-PD-L blockade in acute myeloid Leukemia? Pharmaceuticals (Basel). 2021;14:288.","DOI":"10.3390\/ph14040288"},{"key":"1391_CR61","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40164-022-00263-4","volume":"11","author":"X Yang","year":"2022","unstructured":"Yang X, Ma L, Zhang X, Huang L, Wei J. Targeting PD-1\/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia. Exp Hematol Oncol. 2022;11:11.","journal-title":"Exp Hematol Oncol"},{"key":"1391_CR62","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1182\/blood-2009-03-206672","volume":"114","author":"L Zhang","year":"2009","unstructured":"Zhang L, Gajewski TF, Kline J. PD-1\/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood. 2009;114:1545\u201352.","journal-title":"Blood"},{"key":"1391_CR63","doi-asserted-by":"publisher","first-page":"e1364828","DOI":"10.1080\/2162402X.2017.1364828","volume":"7","author":"S Simon","year":"2017","unstructured":"Simon S, Labarriere N. PD-1 expression on tumor-specific T cells: Friend or foe for immunotherapy?. Oncoimmunology. 2017;7:e1364828.","journal-title":"Oncoimmunology"},{"key":"1391_CR64","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3324\/haematol.2012.066613","volume":"98","author":"MA Sekeres","year":"2013","unstructured":"Sekeres MA, Lancet JE, Wood BL, Grove LE, Sandalic L, Sievers EL, et al. Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica. 2013;98:119\u201328.","journal-title":"Haematologica"},{"key":"1391_CR65","doi-asserted-by":"publisher","first-page":"2030","DOI":"10.1158\/1078-0432.CCR-21-3712","volume":"28","author":"TL Rosenblat","year":"2022","unstructured":"Rosenblat TL, McDevitt MR, Carrasquillo JA, Pandit-Taskar N, Frattini MG, Maslak PG, et al. Treatment of patients with acute myeloid Leukemia with the targeted alpha-particle nanogenerator actinium-225-lintuzumab. Clin Cancer Res. 2022;28:2030\u20137.","journal-title":"Clin Cancer Res"},{"key":"1391_CR66","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/s41375-025-02528-3","volume":"39","author":"SM Abedin","year":"2025","unstructured":"Abedin SM, Guru Murthy GS, Hamadani M, Michaelis LC, Carlson KS, Runaas L, et al. Phase 1 study of lintuzumab-Ac225 combined with CLAG-M salvage therapy in relapsed\/refractory acute myeloid leukemia. Leukemia. 2025;39:837\u201343.","journal-title":"Leukemia"},{"key":"1391_CR67","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1365-2141.2005.05872.x","volume":"132","author":"AM Tsimberidou","year":"2006","unstructured":"Tsimberidou AM, Giles FJ, Estey E, O\u2019Brien S, Keating MJ, Kantarjian HM. The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol. 2006;132:398\u2013409.","journal-title":"Br J Haematol"},{"key":"1391_CR68","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/00001813-200208000-00002","volume":"13","author":"IA Voutsadakis","year":"2002","unstructured":"Voutsadakis IA. Gemtuzumab ozogamicin (CMA-676, Mylotarg) for the treatment of CD33+ acute myeloid leukemia. Anticancer Drugs. 2002;13:685\u201392.","journal-title":"Anticancer Drugs"},{"key":"1391_CR69","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.cell.2018.05.013","volume":"173","author":"MY Kim","year":"2018","unstructured":"Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid Leukemia. Cell. 2018;173:1439\u201353.e19","journal-title":"Cell"},{"key":"1391_CR70","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.immuni.2019.08.012","volume":"51","author":"JG Abelin","year":"2019","unstructured":"Abelin JG, Harjanto D, Malloy M, Suri P, Colson T, Goulding SP, et al. Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction. Immunity. 2019;51:766\u201379.e17","journal-title":"Immunity"},{"key":"1391_CR71","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41587-019-0280-2","volume":"37","author":"B Chen","year":"2019","unstructured":"Chen B, Khodadoust MS, Olsson N, Wagar LE, Fast E, Liu CL, et al. Predicting HLA class II antigen presentation through integrated deep learning. Nat Biotechnol. 2019;37:1332\u201343.","journal-title":"Nat Biotechnol"},{"key":"1391_CR72","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-018-0594-6","volume":"10","author":"C Barra","year":"2018","unstructured":"Barra C, Alvarez B, Paul S, Sette A, Peters B, Andreatta M, et al. Footprints of antigen processing boost MHC class II natural ligand predictions. Genome Med. 2018;10:84.","journal-title":"Genome Med"},{"key":"1391_CR73","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s00251-013-0720-y","volume":"65","author":"E Karosiene","year":"2013","unstructured":"Karosiene E, Rasmussen M, Blicher T, Lund O, Buus S, Nielsen M. NetMHCIIpan-3.0, a common pan-specific MHC class II prediction method including all three human MHC class II isotypes, HLA-DR, HLA-DP and HLA-DQ. Immunogenetics. 2013;65:711\u201324.","journal-title":"Immunogenetics"},{"key":"1391_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202000160","volume":"21","author":"SH Ramarathinam","year":"2021","unstructured":"Ramarathinam SH, Ho BK, Dudek NL, Purcell AW. HLA class II immunopeptidomics reveals that co-inherited HLA-allotypes within an extended haplotype can improve proteome coverage for immunosurveillance. Proteomics. 2021;21:e2000160.","journal-title":"Proteomics"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01391-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01391-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01391-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T06:08:51Z","timestamp":1763446131000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01391-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":74,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1391"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01391-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6307085\/v1","asserted-by":"object"}]},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.G., R.M.R., and N.G.D. are the inventors of the patents associated with this study. N.G.D. is the founder of Leukogene Therapeutics, Inc and owns shares in the company.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"198"}}